![]() ![]() ![]() The baseline of ALT and free IL-6 were found associated with PK/PD parameters during covariates exploration. CRP as the fast-decreasing endpoint and DAS28 as the slow-reacting endpoint were both fitted well through an indirect response model. Apparent systemic clearance was 0.015 L/h, central volume was 8.04 L. A two-compartment model with a sequential zero-first order absorption and a first order elimination best described PK behavior of WBP216. Non-linear mixed effects modeling was used for a population PK/PD analysis. PK, CRP and DAS28 data of WBP216 were collected from 26 RA patients in a single ascending dose study. To optimize the dosage regimen for future clinical trials, pharmacokinetics (PK) and pharmacodynamics (PD) of WBP216 would be firstly characterized in Chinese rheumatoid arthritis (RA) patients. WBP216 is an innovative IL-6 antibody, presenting high affinity to IL-6 and a long half-life (40–60 days). ![]() 3Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.2Key Laboratory of Clinical PK and PD Investigation for Innovative Drugs, Beijing, China.1Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.Xiange Tang 1,2 Xiaofeng Zeng 3 Xiaoduo Guan 1,2 Rui Chen 1,2* Pei Hu 1,2* ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |